A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients

Table 2 Subgroup analyses based on the data of TLR and stent thrombosis; CI - confidence interval, DAPT - dual antiplatelet therapy, RR - risk ratio, TLR - target lesion revascularization

	Stent thrombosis			TLR
Subgroups	No. of studies	RR (95% CI)	Interaction P value	No. of studies	RR (95% CI)	Interaction P value
≤30% patients with insulin therapy	2	0.34 (0.03, 3.43)	0.91	2	0.92 (0.12, 7.32)	0.74
> 30% patients with insulin therapy	5	0.39 (0.22, 0.70)	0.91	4	0.65 (0.46, 0.91)	0.74
DAPT duration = 6 months	2	0.32 (0.09, 1.05)	0.69	2	1.09 (0.67, 1.76)	0.01
DAPT duration = 12 months	6	0.42 (0.23, 0.75)	0.69	5	0.50 (0.34, 0.74)	0.01
< 24-months follow-up	4	0.61 (0.28, 1.30)	0.12	4	0.72 (0.32, 1.58)	0.9
≥24-months follow-up	4	0.26 (0.13, 0.55)	0.12	3	0.68 (0.46, 1.00)	0.9

ISSN: 1749-8090